Selective suppression of de novo SARS-CoV-2 vaccine antibody responses in patients with cancer on B cell–targeted therapy

We assessed vaccine-induced antibody responses to the SARS-CoV-2 ancestral virus and Omicron variant before and after booster immunization in 57 patients with B cell malignancies. Over one-third of vaccinated patients at the pre-booster time point were seronegative, and these patients were predomina...

Descripción completa

Detalles Bibliográficos
Autores principales: Azar, Joseph H., Evans, John P., Sikorski, Madison H., Chakravarthy, Karthik B., McKenney, Selah, Carmody, Ian, Zeng, Cong, Teodorescu, Rachael, Song, No-Joon, Hamon, Jamie L., Bucci, Donna, Velegraki, Maria, Bolyard, Chelsea, Weller, Kevin P., Reisinger, Sarah A., Bhat, Seema A., Maddocks, Kami J., Denlinger, Nathan, Epperla, Narendranath, Gumina, Richard J., Vlasova, Anastasia N., Oltz, Eugene M., Saif, Linda J., Chung, Dongjun, Woyach, Jennifer A., Shields, Peter G., Liu, Shan-Lu, Li, Zihai, Rubinstein, Mark P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Clinical Investigation 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070099/
https://www.ncbi.nlm.nih.gov/pubmed/36749632
http://dx.doi.org/10.1172/jci.insight.163434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070099/
https://www.ncbi.nlm.nih.gov/pubmed/36749632
http://dx.doi.org/10.1172/jci.insight.163434

Ejemplares similares